Immune checkpoint inhibitors that target Programmed Cell Death Protein 1 (PD-1) or Programmed Cell Death Ligand 1 have greatly improved outcomes for patients with many types of cancer; however, only 20–40% of patients benefit from these therapies [7]. The gene discussed is PDCD1; the disease is cancer.